References
- Hansson L, Lithe H, Skoog I, Baro F, Bánki CM, Breteler M, et al. Study on cognition and prognosis in the elderly (SCOPE). Blood Press. 1999;8:177–183.
- Hansson L, Lithe H, Skoog I, Baro F, Bánki CM, Breteler M, et al. Study on cognition and prognosis in the elderly (SCOPE): Baseline characteristics. Blood Press. 2000;9:146–151.
- Lithe H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on COgnition and Prognosis in the Elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertens. 2003; 21:875–886.
- Guidelines Subcommittee. 1999 World Health Organisation—International Society of Hypertension. Guidelines for the management of hypertension. J Hypertens. 1999;17:151–183.
- Progress Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033–1041.
- Dahlöf B, Devereaux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hyper-tension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:995–1003.
- Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, et al., for the RENAAL study investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med. 2001;345: 861–869.
- Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al., for the collaborative study group. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med. 2001;345: 851–860.
- Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet. 2003; 362:1527–1535.
- Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al., for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet. 2004;363:2022–2031.